Please ensure Javascript is enabled for purposes of website accessibility

Why Geron Corporation Stock Popped 84% in March

By Keith Noonan – Apr 13, 2018 at 7:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap oncology biotech's stock is likely to see big movement next week.

What happened

Geron Corporation (GERN 1.30%) stock rose 84% in March, according to data provided by S&P Global Market Intelligence .

GERN Chart

Data source: GERN data by YCharts.

Shares saw significant upward momentum following the company's fourth-quarter earnings release and indications that its blood cancer drug, imetelstat, is producing encouraging trial results. Geron Corporation has a market cap of roughly $600 million, and its valuation is largely dependent on the development and marketing of imetelstat, so shares tend to see big pricing swings in relation to the compound's outlook. 

A pill on a chain swinging into and breaking a wrecking ball.

Image source: Getty Images.

So what

Geron Corporation published fourth-quarter and full-year earnings results on March 16 and held a conference call in which management made comments indicating that trials for imetelstat were yielding favorable results. Imetelstat is an experimental drug and Geron's key product, and the company's shares skyrocketed following management's promising comments.  

Now what

Geron is partnered with Johnson & Johnson (JNJ -0.71%) for the development of imetelstat and is waiting for a decision from the healthcare giant about whether additional testing and development will take place. If J&J opts to pursue development of the drug, Geron will receive a $135 million payment from the company and have the opportunity to receive additional, milestone-based payments.

Johnson & Johnson is due to report earnings on April 17 and is expected to give an update on its clinical trial pipeline on that date. The company has listed imetelstat among its list of potential blockbuster drugs for two years running, and Geron shares will likely see big movement depending on whether its partner once again presents a favorable outlook for the drug.  

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17
Geron Corporation Stock Quote
Geron Corporation
GERN
$2.34 (1.30%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.